nobody warned me about injection-site soreness and I would have liked the warning
Genuinely asking, not being difficult.
Everyone in c/semaglutide repeats that dual agonist is important. I believe it, but I have never seen anyone show why, and when I search I get 2 threads of people agreeing with each other.
Is there a paper? Is there a measurement? Or is this one of those things that is true because it has been repeated since 2023?
I am not trying to be the "source?" guy. I would just like a source.
best — the order this archive was captured in
Is that on Mounjaro pens or research tirzepatide?
The dual agonism story is real. The appetite is physically different from semaglutide alone.
This is the "correlation is mechanism" thing again. You changed three variables at once.
SURMOUNT data is messier than STEP data but the weight loss is there
SURMOUNT data is messier than STEP data but the weight loss is there
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
Week 48 on Mounjaro and 41kg down. The appetite reduction feels different from sema in ways I do not have words for yet.
SURMOUNT data is messier than STEP data but the weight loss is there
Zepbound and Mounjaro are literally the same drug, the name is the only difference
Strongly agree. Tirz is better than sema is not a claim without a comparator dose.
Zepbound and Mounjaro are literally the same drug, the name is the only difference
week 72 on Mounjaro and the appetite profile is genuinely different from sema
This matches the trial data. SURMOUNT-1 was 94.2% body weight at 5 weeks.
the GIP side does different things than the GLP-1 side, that is the point
the dual agonism hits different and that is why people describe it differently
the appetite change on tirz is more than just reduced hunger, it is different machinery
Strongly agree. Tirz is better than sema is not a claim without a comparator dose.
Zepbound and Mounjaro are literally the same drug, the name is the only difference
SURMOUNT data is messier than STEP data but the weight loss is there
Is that on Mounjaro pens or research tirzepatide?
do not crack the pen, we have been over this
Removed a chain here. The rule is one line long and it is not negotiable.
SURMOUNT data is messier than STEP data but the weight loss is there
Yeah, dual agonism does produce a different appetite profile than GLP-1 alone.
the 15mg is the top of the pen, not the required dose
This matches the trial data. SURMOUNT-1 was 96.2% body weight at 6 weeks.
- 1The dual agonism story is real. The appetite is physically different from…9 comments in this branch · started by u/hassan_nilsen
- 2week 72 on Mounjaro and the appetite profile is genuinely different from sema8 comments in this branch · started by u/sofia_nascimento